North Carolina-based, EydisBio, a pharma company recently received a grant of $2.6 million led by EydisBio Received $2.6M Grant By NIH NHLBI (National Institute of Health’s National Heart, Lung, and Blood Institute).
EydisBio $2.6M Grant
CEO EydisBio, Dr. Tim Haystead, said that the grant raised will enable us for TAK1 efficacy research.
EydisBio is a pharma company at an early stage. CEO EydisBio said we are working on a noble cause to treat various autoimmune diseases. The EydisBio TAK1 program demonstrates the preclinical studies. Moreover, the company is working on toxicity studies of GLP-compliant to support IND (Investigational New Drug) trials so that the filing can proceed.
CEO Tim said that EydisBio TAK1 will take the pharma company to a whole new level and unlock new therapeutic treatments.
Also Read: California-Based Orby AI $30M Series